Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Bria-IMT by BriaCell Therapeutics for Metastatic Breast Cancer: Likelihood of Approval
"Bria-IMT is under clinical development by BriaCell Therapeutics and currently in Phase III for Metastatic Breast Cancer. According to GlobalData,...
Bria-IMT by BriaCell Therapeutics for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Bria-IMT is under clinical development by BriaCell Therapeutics and currently in Phase III for Human Epidermal Growth Factor Receptor 2...
Bria-IMT by BriaCell Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Bria-IMT is under clinical development by BriaCell Therapeutics and currently in Phase III for Human Epidermal Growth Factor Receptor 2...
Bria-IMT by BriaCell Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Bria-IMT is under clinical development by BriaCell Therapeutics and currently in Phase III for Triple-Negative Breast Cancer (TNBC). According to...